Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity

Aysim Gunes, Laurent Bilodeau, Catherine Huet, Assia Belblidia, Cindy Baldwin, Jeanne-Marie Giard, Laurent Biertho, Annie Lafortune, Christian Yves Couture, Bich N Nguyen, Eithan Galun, Chantal Bémeur, Marc Bilodeau, Mathieu Laplante, An Tang, May Faraj, View ORCID ProfileJennifer L. Estall
doi: https://doi.org/10.1101/2022.01.10.22268968
Aysim Gunes
1Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada
2Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
3Montreal Diabetes Research Centre, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Bilodeau
4Département de radiologie, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Huet
4Département de radiologie, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Assia Belblidia
4Département de radiologie, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cindy Baldwin
1Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanne-Marie Giard
5Département d’hépatologie, Centre hospitalier de l’Université de Montréal (CHUM), Département de médecine, Université de Montréal, Centre de recherche du CHUM, Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Biertho
6Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Canada
7Département de chirurgie, Faculté de médecine, Université Laval, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annie Lafortune
6Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Canada
7Département de chirurgie, Faculté de médecine, Université Laval, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Yves Couture
6Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Canada
8Département de biologie moléculaire, biochimie médicale et pathologie, Université Laval, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bich N Nguyen
9Département de pathologie et biologie cellulaire, Université de Montréal, Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eithan Galun
10Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Bémeur
11Département de nutrition, Université de Montréal, Montréal, Québec, Canada
12Labo HépatoNeuro, Centre de recherche du CHUM, Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Bilodeau
12Labo HépatoNeuro, Centre de recherche du CHUM, Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Laplante
3Montreal Diabetes Research Centre, Montreal, Quebec, Canada
6Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Canada
13Centre de recherche sur le cancer de l’Université Laval, Université Laval, Québec, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
An Tang
4Département de radiologie, Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
May Faraj
1Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada
3Montreal Diabetes Research Centre, Montreal, Quebec, Canada
11Département de nutrition, Université de Montréal, Montréal, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L. Estall
1Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada
2Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
3Montreal Diabetes Research Centre, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer L. Estall
  • For correspondence: jennifer.estall@ircm.qc.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Interleukin-6 (IL-6) plays important and dynamic roles in inflammation associated with fatty liver disease over all stages, from simple steatosis to steatohepatitis, cirrhosis and cancer. IL-6 signals locally, but also circulates with multiple co-factors that control paracrine and endocrine signaling. As inflammation is a main driver of liver fibrosis, we investigated relationships between circulating components of the interleukin-6 signaling pathway (IL-6, sIL-6R and sgp130) and liver pathology in subjects with metabolically associated fatty liver disease (MAFLD) or steatohepatitis (MASH).

Methods Predictive performances of plasma IL-6, sIL-6R and sgp130 were investigated in two independent cohorts: 1) patients with biopsy-confirmed MASH (n=49), where magnetic resonance spectroscopy (MRS), imaging (MRI) and elastography (MRE) assessed liver fat, volume and stiffness; and 2) patients with morbid obesity (n=245) undergoing bariatric surgery where histological staging of steatosis, activity, and fibrosis determined MASH severity. Correlations were evaluated between IL-6, sIL-6R and sgp130 and anthropomorphic characteristics, plasma markers of metabolic disease or liver pathology.

Results In patients with MASH, plasma IL-6 and sgp130 strongly correlated with liver stiffness, which for sgp130 was independent of age, sex, BMI, diabetes, hyperlipidemia, hypertension or history of HCC. Plasma sgp130 was the strongest predictor of liver stiffness compared to common predictors and risk scores. Plasma sIL-6R correlated with liver volume independent of age, sex, and BMI. In patients with morbid obesity, circulating sgp130 correlated with advanced liver fibrosis.

Conclusion Levels of circulating sgp130 can predict progressing MASH and may be used alone or in combination with other predictors as a non-invasive measure of liver disease severity.

Figure
  • Download figure
  • Open in new tab

Competing Interest Statement

Laurent Biertho receives funding from Johnson & Johnson Medical Companies, Medtronic, Bodynov and GI Windows for studies on bariatric surgery. An Tang and Jennifer Estall received a speaking honorarium from Eli Lilly.

Funding Statement

This work was supported by unrestricted operating grants from the Merck, Sharpe and Dohme Corporation/University of Montreal and the International Development Research Centre (108591-001). JLE and AT are supported by Chercheurs-boursiers: Senior awards from the Fonds de recherche du Quebec Sante. The ULaval Biobank is supported by the IUCPQ Foundation and Research Center.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethics committees of the: Centre hospitalier de Universite de Montreal; Institut de recherches clinique de Montreal; and Institut universitaire de cardiologie et de pneumologie de Quebec, Universite Laval gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Abbreviations: NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; MAFLD, metabolically-associated fatty liver disease; MASH, metabolically-associated steatohepatitis, MASH; hepatocellular carcinoma, (HCC); interleukin-6, IL-6; soluble interleukin-6 receptor (sIL-6R); glycoprotein 130, gp130; magnetic resonance spectroscopy, MRS; imaging, MRI; elastography, MRE; alanine and aspartate aminotransferases, ALT and AST; gamma glutamyl transferase, GGT; NAFLD activity score NAS; NAFLD activity fibrosis score, SAF; FIB-4 index, fibrosis-4 index; APRI score, AST to platelet platelet ratio.

  • Conflict of interest statement: Laurent Biertho receives funding from Johnson & Johnson Medical Companies, Medtronic, Bodynov and GI Windows for studies on bariatric surgery. An Tang and Jennifer Estall received a speaking honorarium from Eli Lilly. A Gunes, L Bilodeau, C Huet, A Belblidia, C Baldwin, JM Giard, A Lafortune, CY Couture, BN Nguyen, E Galun, C Bémeur, M Bilodeau, M Laplante, and May Faraj have nothing to disclose.

  • Data Transparency: The data, analytic methods and study materials is available for other researchers upon request.

  • Funding: This work was supported by unrestricted operating grants from the Merck, Sharpe and Dohme Corporation/University of Montreal and the International Development Research Centre (108591-001). JLE and AT are supported by Chercheurs-boursiers: Senior awards from the Fonds de recherche du Québec Santé. The ULaval Biobank is supported by the IUCPQ Foundation and Research Center.

  • Figures have been reformatted. Introduction and discussion have been modified to include mechanistic implications of our work.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 25, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity
Aysim Gunes, Laurent Bilodeau, Catherine Huet, Assia Belblidia, Cindy Baldwin, Jeanne-Marie Giard, Laurent Biertho, Annie Lafortune, Christian Yves Couture, Bich N Nguyen, Eithan Galun, Chantal Bémeur, Marc Bilodeau, Mathieu Laplante, An Tang, May Faraj, Jennifer L. Estall
medRxiv 2022.01.10.22268968; doi: https://doi.org/10.1101/2022.01.10.22268968
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity
Aysim Gunes, Laurent Bilodeau, Catherine Huet, Assia Belblidia, Cindy Baldwin, Jeanne-Marie Giard, Laurent Biertho, Annie Lafortune, Christian Yves Couture, Bich N Nguyen, Eithan Galun, Chantal Bémeur, Marc Bilodeau, Mathieu Laplante, An Tang, May Faraj, Jennifer L. Estall
medRxiv 2022.01.10.22268968; doi: https://doi.org/10.1101/2022.01.10.22268968

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1101)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9785)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2319)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11657)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2149)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2188)
  • Public and Global Health (4674)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)